Skip to main navigation Skip to search Skip to main content

Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives

  • Johannes Sievers
  • , Rabea Voget
  • , Feiteng Lu
  • , Kathleen M. Garchitorena
  • , Yuen Lam Dora Ng
  • , Cindy H. Chau
  • , Christian Steinebach
  • , William D. Figg
  • , Jan Krönke
  • , Michael Gütschow*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Introduction of fluorine into bioactive molecules has attracted much attention in drug development. For example, tetrafluorination of the phthalimide moiety of immunomodulatory drugs (IMiDs) has a strong beneficial effect on the ability to inhibit angiogenesis. The neomorphic activity of E3 ligase complexes is induced by the binding of IMiDs to cereblon. We investigated that a set of eight thalidomide analogs, comprising non- and tetrafluorinated counterparts, did not induce the degradation of neomorphic substrates (IKZF3, GSPT1, CK1α, SALL4). Hence, the antiangiogenic activity of fluorinated IMiDs was not triggered by neosubstrate degradation features. A fluorine scanning of non-traditional IMiDs of the benzamido glutarimide chemotype was performed. By measuring the endothelial cell tube formation, no angiogenesis inhibitors were identified, confirming the narrow structure–activity window of IMiD-induced antiangiogenesis.

Original languageEnglish
Article number129858
JournalBioorganic and Medicinal Chemistry Letters
Volume110
DOIs
StatePublished - 15 Sep 2024

Keywords

  • Angiogenesis
  • Cancer therapy
  • Cereblon
  • Immunomodulatory drugs
  • Neosubstrates

Fingerprint

Dive into the research topics of 'Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives'. Together they form a unique fingerprint.

Cite this